Zobrazeno 1 - 10
of 380
pro vyhledávání: '"Craig A. Jordan"'
Autor:
Deepak M. Sahasrabudhe, Jane L. Liesveld, Mohammad Minhajuddin, Niloy A. Singh, Subhangi Nath, Vishuwes Muthu Kumar, Marlene Balys, Andrew G. Evans, Mitra Azadniv, Jeanne N. Hansen, Michael W. Becker, Ashoke Sharon, V. Kaye Thomas, Richard G. Moore, Manoj K. Khera, Craig T. Jordan, Rakesh K. Singh
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-17 (2024)
Abstract Acute myeloid leukemia (AML) is fatal in the majority of adults. Identification of new therapeutic targets and their pharmacologic modulators are needed to improve outcomes. Previous studies had shown that immunization of rabbits with normal
Externí odkaz:
https://doaj.org/article/8cb79daf4e1a4e33924367fab7865cf3
Autor:
Nazmul Islam, Jamie S Reuben, Justin Dale, James W Coates, Karan Sapiah, Frank R Markson, Craig T Jordan, Clay Smith
Publikováno v:
JMIR Cancer, Vol 10, p e54740 (2024)
BackgroundThe treatment of acute myeloid leukemia (AML) in older or unfit patients typically involves a regimen of venetoclax plus azacitidine (ven/aza). Toxicity and treatment responses are highly variable following treatment initiation and clinical
Externí odkaz:
https://doaj.org/article/c7f1cc1779ca40a9bdd9fb999aeb7eef
Autor:
Mohd Minhajuddin, Amanda Winters, Haobin Ye, Shanshan Pei, Brett Stevens, Austin Gillen, Krysta Engel, Stephanie Gipson, Monica Ransom, Maria Amaya, Anagha Inguva, Maura Gasparetto, Mark J. Althoff, Regan Miller, Ian Shelton, Hunter Tolison, Anna Krug, Rachel Culp-Hill, Angelo D’Alessandro, Daniel W Sherbenou, Daniel A. Pollyea, Clayton Smith, Craig T Jordan
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
The treatment of blast phase chronic myeloid leukemia (bpCML) remains a challenge due at least in part to drug resistance of leukemia stem cells (LSCs). Recent clinical evidence suggests that the BCL-2 inhibitor venetoclax in combination with ABL-tar
Externí odkaz:
https://doaj.org/article/1e698dc2b5034f73b534561525fe0273
Autor:
Amanda C. Winters, Mohd Minhajuddin, Brett M. Stevens, Ajay Major, Grace Bosma, Diana Abbott, Nicholas Miltgen, Ji Yuan, Amy L. Treece, Bradford J. Siegele, Mark D. Ewalt, Jonathan A. Gutman, Craig T. Jordan, Daniel A. Pollyea
Publikováno v:
Haematologica, Vol 109, Iss 6 (2023)
Venetoclax with azacitidine (ven/aza) is a lower-intensity therapeutic regimen that has been shown to improve outcomes in elderly patients with acute myeloid leukemia (AML). Measurable residual disease (MRD) using flow cytometry is a valuable tool fo
Externí odkaz:
https://doaj.org/article/dd1f3941b21d43f7a99618a3961ccd30
Autor:
Maria Amaya, Christine Mcmahon, Jonathan Aaron Gutman, Marc Schwartz, Brett Sevens, Connor Sohalski, Jennifer Tobin, Clayton Smith, Craig T Jordan, Daniel Aaron Pollyea
Publikováno v:
HemaSphere, Vol 7, p e95778ba (2023)
Externí odkaz:
https://doaj.org/article/51e1c577cf504e6fa7f5e47e3ec7d7f7
Autor:
Jonathan A. Gutman, Amanda Winters, Andrew Kent, Maria Amaya, Christine McMahon, Clayton Smith, Craig T. Jordan, Brett Stevens, Mohammad Minhajuddin, Shanshan Pei, Jeffrey Schowinsky, Jennifer Tobin, Kelly O’Brien, Angela Falco, Elizabeth Taylor, Constance Brecl, Katie Zhou, Phuong Ho, Connor Sohalski, Jessica Dell-Martin, Olivia Ondracek, Diana Abbott, Daniel A. Pollyea
Publikováno v:
Haematologica, Vol 108, Iss 10 (2023)
Venetoclax+azacitidine is the standard of care for newly-diagnosed patients with acute myeloid leukemia (AML) for whom intensive chemotherapy is inappropriate. Efforts to optimize this regimen are necessary. We designed a clinical trial to investigat
Externí odkaz:
https://doaj.org/article/4bed77ea2bb644d486a34c85f8f12b19
Autor:
Hae J Park, Mark A Gregory, Vadym Zaberezhnyy, Andrew Goodspeed, Craig T Jordan, Jeffrey S Kieft, James DeGregori
Publikováno v:
eLife, Vol 11 (2022)
While leukemic cells are susceptible to various therapeutic insults, residence in the bone marrow microenvironment typically confers protection from a wide range of drugs. Thus, understanding the unique molecular changes elicited by the marrow is of
Externí odkaz:
https://doaj.org/article/ea84268fcc014d5baa026f0532c4b188
Autor:
Ross Gore, Christopher J Lynch, Craig A Jordan, Andrew Collins, R Michael Robinson, Gabrielle Fuller, Pearson Ames, Prateek Keerthi, Yash Kandukuri
Publikováno v:
JMIR Public Health and Surveillance, Vol 8, Iss 8, p e37379 (2022)
BackgroundAdding additional bicycle and pedestrian paths to an area can lead to improved health outcomes for residents over time. However, quantitatively determining which areas benefit more from bicycle and pedestrian paths, how many miles of bicycl
Externí odkaz:
https://doaj.org/article/bf35fd8a354a4931a88acb872933235d
Autor:
Hanan Alwaseem, Simone Giovani, Michele Crotti, Kevin Welle, Craig T. Jordan, Sina Ghaemmaghami, Rudi Fasan
Publikováno v:
ACS Central Science, Vol 7, Iss 5, Pp 841-857 (2021)
Externí odkaz:
https://doaj.org/article/7fb1f4907aaf4ca48e778ec8357799ef
Autor:
Rachel Culp-Hill, Brett M. Stevens, Courtney L. Jones, Shanshan Pei, Monika Dzieciatkowska, Mohammad Minhajuddin, Craig T. Jordan, Angelo D’Alessandro
Publikováno v:
Metabolites, Vol 13, Iss 4, p 467 (2023)
Recent advances in targeting leukemic stem cells (LSCs) using venetoclax with azacitidine (ven + aza) has significantly improved outcomes for de novo acute myeloid leukemia (AML) patients. However, patients who relapse after traditional chemotherapy
Externí odkaz:
https://doaj.org/article/65d7f53879dc4307ac50c0ab77af4dac